Go Pro
OTCMKTS:LABFF

Laboratorios Farmaceuticos Rovi (LABFF) Stock Price, News & Analysis

Laboratorios Farmaceuticos Rovi logo
C$67.17 0.00 (0.00%)
As of 08/12/2026

About Laboratorios Farmaceuticos Rovi Stock (OTCMKTS:LABFF)

Advanced

Key Stats

Today's Range
C$67.17
C$67.17
50-Day Range
C$64.77
C$67.17
52-Week Range
C$65.86
C$67.17
Volume
N/A
Average Volume
1,300 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Laboratorios Farmacéuticos ROVI S.A. is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology. The ISM platform enables once-monthly administration without the need for cold-chain handling, supporting patient adherence in outpatient and institutional settings. In recent years, the company has advanced its R&D pipeline with new injectable candidates in partnership with global pharmaceutical firms.

Headquartered in Madrid, Spain, ROVI maintains multiple manufacturing facilities in Europe and has established a presence in key markets across the European Union, Latin America and Asia. Through licensing agreements and collaborative supply arrangements, the company supplies both branded and unbranded products in over 40 countries. ROVI is also expanding its commercial footprint in North America via partnerships with specialty pharmaceutical distributors.

Founded in 1946, ROVI has grown from a domestic heparin producer into a global specialty pharma company with a focus on differentiated injections and biosimilars. With ongoing investments in its production network and technology platforms, ROVI aims to support sustainable growth by addressing unmet needs in chronic and hospital-based therapies.

AI Generated. May Contain Errors.

Receive LABFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratorios Farmaceuticos Rovi and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LABFF Stock News Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Headlines

LABFF Stock Analysis - Frequently Asked Questions

Laboratorios Farmaceuticos Rovi's stock was trading at C$65.86 at the beginning of 2026. Since then, LABFF stock has increased by 2.0% and is now trading at C$67.17.

Shares of LABFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:LABFF
CIK
N/A
Fax
N/A
Employees
1,925
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (OTCMKTS:LABFF) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners